Synonyms: ANG-3070 | ANG3070 | Example 1 [WO2013112959A1]
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for ansornitinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase kinase inhibitor. Ansornitinib may be ANG-3070, an oral tyrosine kinase inhibitor that was developed by Angion Biomedica for anti-fibrotic potential in kidney diseases, such as focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Clinical trial of ANG-3070 was terminated in June 2022, following an unexpected and dangerous decline in kidney function in a patient who received the drug treatment. Development for idiopathic pulmonary fibrosis appears to be continuing.
|
|
Bioactivity Comments |
WO2013112959A1 claims that this compound inhibits the cellular activity of the VEGF receptor KDR and PDGFRα and β [1], but we have been unable to find quantitative data for ansornitinib at either of these proposed molecular targets. |